Company intelligence / Profile preview

Yuan Yuan

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Yuanyuan Biotech is a Shanghai-based biotechnology company specializing in the development of next-generation gene therapies. The company focuses on engineering novel Adeno-associated virus (AAV) capsids with improved tissue specificity and reduced immunogenicity using its proprietary screening platform. Their primary therapeutic focus includes central nervous system (CNS) disorders, neuromuscular diseases, and metabolic conditions. Founded by experts in viral vector engineering, Yuanyuan Biotech aims to overcome the current limitations of AAV delivery to provide more effective treatments for rare and common genetic diseases.

Therapeutic areas: NeurologyRare DiseasesMetabolic Disorders
Modalities: Gene therapyAAV
Industry: Biotech

Beyond the preview

Go deeper on Yuan Yuan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuan Yuan.

Explore the full profile